Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.).

The company stated that while the compound demonstrated efficacy signals across all time points, the trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Scale) score at 24 hours compared to placebo. MADRS is …

Full story available on Benzinga.com